HOUSTON, Texas, May 18, 2020 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology, today
announced that the results from its pivotal cellulite trial have
been accepted for virtual video presentation at the American
Academy of Dermatology (AAD) 2020 Virtual Meeting, being held
June 12-14, 2020 online at aad.org.
The AAD adopted this new virtual format as a result of their annual
conference being cancelled due to the COVID-19 crisis.
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
"We are thrilled that our pivotal cellulite data will be
presented through the AAD's virtual format by leading dermatologist
Dr. Elizabeth Tanzi," stated
Christopher Capelli, MD, founder,
President and CEO of Soliton. "Globally, cellulite affects between
80-90% of women and there is approximate $2.4 billion per year spent globally on
treatment, making it an attractive market for our RAP device.
We believe our RAP device is uniquely capable of selective
disruption of the fibrotic septa that contribute to the appearance
of cellulite, called acoustic subcision. We look forward to
sharing the pivotal results regarding the potential of the RAP
device to be a solution to improve the unwanted appearance of
cellulite."
Dr. Tanzi is a member of Soliton's Scientific Advisory
Board.
While only paid attendees of the conference will be able to view
the presentation, the Company will provide trial results publicly
shortly after the conference.
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson
Cancer Center ("MD Anderson"). The Company's first FDA cleared
commercial product will use rapid pulses of acoustic shockwaves as
an accessory to lasers for the removal of unwanted tattoos. The
Company is based in Houston,
Texas, and is actively engaged in bringing the Rapid
Acoustic Pulse ("RAP") device to the market. The Company believes
this "Soliton" method has the potential to lower tattoo removal
costs for patients, while increasing profitability to
practitioners, compared to current laser removal methods.
Soliton is investigating potential additional capabilities of the
RAP technology in preclinical testing, including the potential to
assist existing fat reduction technology in the reduction of fat as
well as improving the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of the Soliton RAP
device to demonstrate safety and efficacy in the reduction of
cellulite and the ability for Soliton to receive FDA clearance for
this additional indication. These statements relate to future
events, future expectations, plans and prospects. Although Soliton
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. Soliton has
attempted to identify forward-looking statements by terminology
including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under in our SEC filings, including under the heading "Item 1A.
Risk Factors" in the Form 10-K for year ended December 31, 2019 we filed with the SEC and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-announces-pivotal-cellulite-clinical-trial-results-to-be-presented-at-aad-virtual-meeting-june-12-14-301060512.html
SOURCE Soliton, Inc.